Updated on 28 September 2012
Bangalore: India-based Dr. Reddy's Laboratories has launched its montelukast sodium oral granules, a bioequivalent generic version of Singulair oral granules in the US market. The launch follows an approval by the US Food & Drug Administration (FDA) of Dr. Reddy's ANDA for montelukast sodium oral granules.
The Singulair oral granules brand had US sales of approximately $61 million for the most recent twelve months ending July 2012 according to IMS Health.
Dr. Reddy's Montelukast Sodium Oral Granules in 4 mg will be available in unit dosage package of 30.
Survey Box
Subscribe to BioSpectrum Asia digital mag at an attractive price of US $49.99 a year
(Includes all 24 regular & special issues @ fortnightly frequency)
Send this article by email
Australia
China
India
Japan
Korea
Malaysia
New Zealand 
Singapore
Taiwan
Thailand
